Tenax Therapeutics (TENX) CEO exercises options, adds 8,719 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026 to acquire 8,719 common shares, including 8,500 shares at $5.94 per share and 219 shares at $3.549 per share. The aggregate exercise price for these options was paid in cash.
After the exercises, he directly owned 11,324 and 2,824 common shares in the reported accounts and continued to hold stock options covering 1,400,000 shares at a $5.89 exercise price and 450,000 shares at a $13.30 exercise price, with vesting schedules extending over several years and expirations in 2035 and 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
8,719 shares exercised/converted
Mixed
8 txns
Insider
Giordano Christopher Thomas
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 219 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 8,500 | $0.00 | -- |
| Exercise | Common Stock | 219 | $3.549 | $777.23 |
| Exercise | Common Stock | 8,500 | $5.94 | $50K |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 218 shares (Direct);
Common Stock — 2,824 shares (Direct)
Footnotes (1)
- The aggregate exercise price was paid in cash. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
Key Figures
Shares acquired via option exercise: 8,719 shares
Exercise price per share: $5.94
Exercise price per share: $3.549
+4 more
7 metrics
Shares acquired via option exercise
8,719 shares
Total common shares acquired through option exercises on July 13, 2026
Exercise price per share
$5.94
Exercise price for 8,500-share stock option exercised into common stock
Exercise price per share
$3.549
Exercise price for 219-share stock option exercised into common stock
Direct common shares held
11,324 shares
Direct common shares held after one of the exercise-related transactions
Direct common shares held
2,824 shares
Direct common shares held after the second exercise-related transaction
Unexercised option position
1,400,000 underlying shares
Stock option on 1,400,000 shares at $5.89, expiring May 16, 2035
Unexercised option position
450,000 underlying shares
Stock option on 450,000 shares at $13.30, expiring January 9, 2036
Key Terms
Stock Option (right to buy), exercise price, vest and become exercisable, aggregate exercise price
4 terms
Stock Option (right to buy) financial
"security_title shows Stock Option (right to buy) for derivative holdings"
exercise price financial
"conversion_or_exercise_price fields list the option exercise price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"Footnotes describe when options vest and become exercisable over several years"
aggregate exercise price financial
"A footnote states the aggregate exercise price was paid in cash"
FAQ
What insider activity did Tenax Therapeutics (TENX) report for its CEO?
Tenax Therapeutics reported that CEO Christopher Thomas Giordano exercised stock options on July 13, 2026 to acquire 8,719 common shares. These were derivative exercises of existing options rather than open-market stock purchases.
How were the TENX option exercises by the CEO paid for?
According to the report’s footnotes, the aggregate exercise price was paid in cash for the options exercised by the CEO. This indicates the transactions were cash-paid exercises rather than net or cashless exercises using previously held shares.
What unexercised TENX stock options does the CEO still hold?
The CEO continues to hold stock options on 1,400,000 shares at a $5.89 exercise price and 450,000 shares at a $13.30 exercise price, plus smaller grants of 157 and 125 underlying shares at higher exercise prices, with expirations ranging from 2031 to 2036.
How do the CEO’s TENX stock options vest over time?
Footnotes state several option awards vest 25% on a specified date and 25% annually1/36 of remaining shares monthly